Loading clinical trials...
Loading clinical trials...
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
Conditions
Interventions
AT7519M
Bortezomib
Locations
5
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Faber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan-Kettering Cancer Centre
New York, New York, United States
MCW and Froedtert Clinical Cancer Center, Division of Neoplastic Diseases & Related Disorders
Milwaukee, Wisconsin, United States
Start Date
November 1, 2010
Primary Completion Date
December 1, 2014
Completion Date
March 1, 2015
Last Updated
August 2, 2024
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Astex Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions